Upadacitinib Global Market Report 2025

The upadacitinib market size has grown rapidly in recent years. It will grow from $1.32 billion in 2024 to $1.51 billion in 2025 at a compound annual growth rate (CAGR) of 14.8%. The growth during the historic period can be attributed to the rising incidence of autoimmune diseases, the expansion of patient assistance programs, an increase in positive regulatory approvals across various countries, higher disposable incomes, and improvements in healthcare infrastructure.

The upadacitinib market size is expected to see rapid growth in the next few years. It will grow to $2.6 billion in 2029 at a compound annual growth rate (CAGR) of 14.5%. The projected growth in the forecast period is driven by the increasing incidence of rheumatoid arthritis, the expansion of patient assistance programs, greater acceptance of traditional DMARDs, government initiatives to raise awareness of rheumatoid arthritis symptoms, and a rise in FDA approvals for treatment. Key trends include the adoption of targeted therapies and biomarkers, real-world data analysis, a stronger emphasis on value-based care, the development of specialized JAK inhibitors, and advancements in biologics.

The increasing incidence of autoimmune diseases is expected to drive the growth of the upadacitinib market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells, misidentifying them as foreign threats. The rising occurrence of these diseases is attributed to genetic predisposition, environmental triggers, and shifts in lifestyle and immune system function. Upadacitinib plays a crucial role in managing autoimmune conditions by selectively inhibiting JAK1, thereby reducing inflammation and modulating immune responses in disorders such as rheumatoid arthritis and psoriatic arthritis. For instance, in November 2024, Versorgungsatlas de, a Germany-based healthcare data analytics company, reported that 6,304,340 individuals were diagnosed with at least one autoimmune disease in 2022, corresponding to a raw prevalence rate of 8.61%. As a result, the increasing prevalence of autoimmune diseases is fueling the expansion of the upadacitinib market.

Companies operating in the upadacitinib market are prioritizing the development of innovative treatments, such as oral Janus kinase (JAK) inhibitors, to enhance options for managing autoimmune diseases. These oral inhibitors are small-molecule drugs that block Janus kinase enzymes, suppressing excessive immune activity and inflammation to effectively treat autoimmune and inflammatory conditions. For example, in April 2023, AbbVie Inc., a US-based pharmaceutical company, announced that RINVOQ (upadacitinib) had received European Commission approval for the treatment of moderately to severely active Crohn's disease. This oral formulation enables once-daily administration, improving patient adherence and treatment convenience. Compared to traditional therapies, the oral delivery method provides a faster onset of action, making it easier for patients to maintain their treatment regimens.

In November 2022, Caplin Point Laboratories Limited, an India-based pharmaceutical company, acquired an API plant from Metrochem API Private Limited for an undisclosed amount. This acquisition strengthens Caplin Point Laboratories' capacity to manufacture a wider range of high-quality API products, reinforcing its supply chain and expanding its reach in regulated markets. Metrochem API Private Limited, also based in India, is a pharmaceutical company involved in the production of upadacitinib.

Major players in the upadacitinib market are Merck & Co. Inc., AbbVie Inc, Eli Lilly and Company, Curia Global Inc., Egis Pharmaceuticals PLC, Natco Pharma, Morepen Laboratories, Zhejiang Hengkang Pharmaceutical, Sinoway industrial Co. Ltd., Optimus Pharma, Venkatasai Life Sciences, Shandong Chenghui Shuangda Pharmaceutical Co. Ltd., Jinan Tantu Chemicals Co. Ltd., Shandong Loncom Pharmaceutical Co. Ltd., Lee Pharma, TAPI Technology & API Services, Hebi Xinhe Pharmaceutical, Suzhou PengXu PharmaTech Co. Ltd., Anhui Dexinjia Biopharm Co. Ltd., Sichuan Qingmu Pharmaceutical Co. Ltd., Shandong Boyuan Pharmaceutical.

North America was the largest region in the upadacitinib market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in upadacitinib report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the upadacitinib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Upadacitinib is a Janus kinase (JAK) inhibitor used to treat various inflammatory conditions by targeting and inhibiting specific enzymes involved in the inflammatory process. It is prescribed for moderate to severe rheumatoid arthritis (RA) and other autoimmune diseases, offering a targeted therapy alternative to traditional disease-modifying anti-rheumatic drugs (DMARDs) and biologics, with the added convenience of oral administration.

The primary product types of upadacitinib include Janus kinase inhibitors, antirheumatic agents, and small molecule drugs. Janus kinase (JAK) inhibitors work by blocking the activity of Janus kinase enzymes to reduce inflammation and manage autoimmune diseases. Upadacitinib is used for various applications, such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease, and is utilized by multiple end users, including hospitals, home care, specialty clinics, and others.

The upadacitinib market research report is one of a series of new reports that provides upadacitinib market statistics, including the upadacitinib industry global market size, regional shares, competitors with the upadacitinib market share, detailed upadacitinib market segments, market trends, and opportunities, and any further data you may need to thrive in the upadacitinib industry. This upadacitinib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The upadacitinib market consists of sales of immunosuppressants and anti-inflammatory agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.